Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2016-01-01
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetic Architecture of Natriuretic Peptides and Blood Pressure Response
NCT07118592
B-type Natriuretic Peptide (BNP) in Human Hypertension
NCT00953472
The Natriuretic Peptide System in African-Americans.
NCT02730780
Renal Metabolism in Salt-sensitive Human Blood Pressure
NCT05369416
Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
NCT00387621
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Research design: Individuals with physiological levels of NT-proBNP (40 - 90 pg/mL) and those with elevated levels (\> 120 pg/mL) will be recruited to participate in a randomized crossover feeding study designed to treat patients with hypertension. A total of 8 participants, per group, will be exposed to two 10 days-phases of either a low sodium load (LS) of 50 mmol/day or a high sodium load (HS) of 250 mmol/day in random order and compare the blood pressure response to different sodium loads between the two NT-proBNP categories. Salt sensitivity is defined as a change in mean arterial blood pressure of ≥ 10% between the low and high sodium load. At the end of each phase, participants will be tested on a variety of anthropometric, blood and urinary measurements.
Variables measured: Total body water will be determined using bioelectrical impedance from Valhalla Scientific body comp scale®. Blood pressure monitors will be provided to each participant for measurement and record their own blood pressure twice daily for the duration of the study. In addition, at the end of each of the two sodium loading phases, trained personnel will measure BP three time using standard procedures, following an 8 hour fast and a 10 minute rest period at the clinic. Laboratory measurements. Blood and urine analysis will be performed at the start and end of each salt loading phase at the Advanced Research and Diagnostic Laboratory (ARDL). NT-proBNP will be measured using the Roche-Elecsys proBNP® (Roche Diagnostics, Indianapolis, IN). This method has a range of values that extends from 1 - 25000 pg/mL and the intra-assay precision is below 4% and the CV and interassay precision below 5% 21. Plasma BNP will be measured on a Siemens Advia Centaur instrument using a chemiluminescent immunoassay which has a minimal detection limit of 1.9 pg/mL and a CV of 3.4%. cGMP will be measured using a competitive enzyme immunoassay by Bio-Techne (Minneapolis, MN) intra essay CV is 7%. NT-proBNP will be measured using the Roche-Elecsys proBNP® (Roche Diagnostics, Indianapolis, IN). This method has a range of values that extends from 1 - 25000 pg/mL and the intra-assay precision is below 4% CV and inter-assay precision below 5% 21.
Anticipated results and future studies. Individuals with elevated NT-proBNP will have a significant increase in mean blood pressure and total body water (salt sensitive individuals) and a greater BNP/cGMP ratio when compared to those with physiological levels of NT-proBNP.
Power analysis shows that for a randomized cross-over study we would need 25 individuals per group for a 90% power.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CROSSOVER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
High and low salt diets
Effects of high and low salt diets on blood pressure in individuals with normal and elevated levels of NT-proBNP
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diastolic blood pressure \> 80 and \< 100 mmHg
3. Not on hypertensive medications
4. NT-proBNP between 40 - 99 pg/mL (healthy levels)
5. NT-proBNP \> 120 pg/mL (elevated levels)
Exclusion Criteria
2. BMI \> 40kg/m2
3. Age \< 30 or \> 75 years
4. Presence of cardiovascular disease or chronic kidney disease
5. Chronic obstructive pulmonary disease or pulmonary arterial hypertension
6. Aldosterone secreting disorder
7. Estimated energy intake greater than 3400 calories
8. Pregnancy
9. Individuals with pacemakers
30 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Otto A Sanchez, MD PhD
Role: PRINCIPAL_INVESTIGATOR
University of Minnesota
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Minnesota Medical Center
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1512M81431
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.